2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 243-245
Access, Representation, Population Health, Treatment Considerations, Non-Biological Therapies, Opioids, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

577 Integrating palliative care into a comprehensive lifespan sickle cell center demonstrates sustained improvement in length of stay and cost of care.

Crawford John Strunk, MD, Kyle Neale, DO2, Consuela Albright, MSN, CNP3, Elizabeth Weinstein, MD, MS4, Katrina Seedhouse, RN, BSN5, Anandita Ghosh, MD6, Rabi Hanna, MD7, Vicente Velez, MD8, Kimberlee Fong, DO9, Ravi Talati, DO10
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States

Introduction:  Sickle cell disease affects over 100,000 people in the United States (Hassel K, Am J Prev Med 2010), and pain is the hallmark of the disease.  Vaso-Occlusive Crises (VOCs) account for 84% of hospital admissions in adults, which significantly affects quality of life and health care utilization (Cronin et al, Hematol 2019).   The average length of stay is 5 days in all ages including children with almost a third of patients readmitted within 30 days, costing over $800 million dollars per year in healthcare costs (HCUP 2016).  Despite evidence that palliative care (PC) interventions help improve quality of life and reduce healthcare utilization (Horton JR et al, J Palliat Med 2016), fewer than 1% of admissions (Nwogu-Onyemkpa E et al, BMJ Open 2022) result in palliative care consultation.

The Cleveland Clinic Sickle Cell Medical Neighborhood (SCMN), established in 2020, is a lifespan sickle cell clinic providing comprehensive care for children and adults, including referrals to all subspecialty care.  The SCMN and the PC team developed an integrated care model in November 2023, and operationalized PC inpatient and Hematology consult services that, in its first year, reduced length of stay from 9 days to 3 days over the course of the year from April 2024 through March 2025 (Strunk et al, Blood 2025).  As part of the care model, individualized care plans were developed and implemented, PC established outpatient follow-up for management of chronic pain, and ongoing consultation for outpatient and inpatient pain management was initiated across the regional hospital system.

This quality improvement project aims to characterize our patient population by utilization for the purposes of developing interventions to decrease utilization, determine if average length of stay (ALOS) can be maintained at the national average, and evaluate cost savings with improved length of stay.

Methods: Data were analyzed from April 2025 through March 2026.  Patients were included in this dataset if they were enrolled in the SCMN database.  Patients were characterized by utilization (non-, non-high, high-, and super-utilizing patients), similar to Koch et al (Koch et al, Am J Hematol 2015) in order to prioritize care improvement strategies and to develop pain plans for our highest utilizing patients. Cost savings were calculated and presented descriptively as a percent reduction in the average of the combined sum of technical and professional direct cost statistics from the global encounter database year over year from 2025 and 2026.  PC and Sickle cell team consultations, individualized care plans, and other quality improvements instituted previously were maintained over the course of this project.

Results:
 Over the time covered by this project, the SCMN grew from 226 patients to 264 patients.  Of these, 130 patients (49%) were non-utilizers (0 ED/admits per year), 84 patients (32%) were non-high utilizers (1-4 ED/admits per year) accounting for 14% of total utilization, 29 patients (11%) were high utilizers (5-11 ED/admits per year) representing 18% of utilization and 21 patients (8%) were super utilizers (>12 ED/admits per year) accounting for 68% of total utilization.  Despite the growth in the SCMN, ALOS averaged 4.12 days (range 3.62-5.17 days), while admission rates were 1.55 admissions per patient per year or the whole cohort or 3.06 admissions per patient per year for all utilizing patients.  Costs per admission from 2025 averaged $8666, while in 2026 the cost was $7876, a reduction of 9%.

Conclusions: Incorporating PC into a comprehensive sickle cell care model shows sustained improvement in length of stay, overall pain management and improvement in cost of care.  While cost of care improvement was demonstrated, gene therapy admissions for stem cell collections may have been included in SCMN admissions, potentially affecting cost.  Future quality improvement should include strategies to reduce ED utilization and admissions in the high- and super-utilizing patients.  However, this model demonstrates sustained results that could be duplicated throughout the region and the state.

Crawford John Strunk, MD: Pfizer - Consultancy (Includes expert testimony); Spark Healthcare - Consultancy (Includes expert testimony)